OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Drug Discovery is 81. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Engineering precision nanoparticles for drug delivery	3967
Natural products in drug discovery: advances and opportunities	2505
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy	1328
PROTAC targeted protein degraders: the past is prologue	1298
Trends in peptide drug discovery	1005
Noncoding RNA therapeutics — challenges and potential solutions	896
Emerging concepts in the science of vaccine adjuvants	761
Macrophages as tools and targets in cancer therapy	752
mRNA vaccines for infectious diseases: principles, delivery and clinical translation	734
Kinase drug discovery 20 years after imatinib: progress and future directions	600
Targeting inflammation in atherosclerosis — from experimental insights to the clinic	544
Strategies for delivering therapeutics across the blood–brain barrier	535
Targeting cancer metabolism in the era of precision oncology	523
Anti-obesity drug discovery: advances and challenges	479
Channelling inflammation: gasdermins in physiology and disease	416
Trends in kinase drug discovery: targets, indications and inhibitor design	410
Antisense technology: an overview and prospectus	371
Therapeutically harnessing extracellular vesicles	369
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics	360
B cell depletion therapies in autoimmune disease: advances and mechanistic insights	347
The clinical landscape for AAV gene therapies	334
FDA approves 100th monoclonal antibody product	328
Advances in covalent drug discovery	305
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease	304
Targeting HER2-positive breast cancer: advances and future directions	296

Advances in TRP channel drug discovery: from target validation to clinical studies	293
Navigating CAR-T cells through the solid-tumour microenvironment	292
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans	277
Targeted protein degraders crowd into the clinic	274
The foundations of immune checkpoint blockade and the ipilimumab approval decennial	274
Beyond immune checkpoint blockade: emerging immunological strategies	266
Drugging p53 in cancer: one protein, many targets	263
Emerging therapeutic opportunities for integrin inhibitors	262
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials	256
PI3K inhibitors are finally coming of age	252
Image-based profiling for drug discovery: due for a machine-learning upgrade?	249
Targeting RNA structures with small molecules	248
Identification of neoantigens for individualized therapeutic cancer vaccines	248
Therapeutic strategies for COVID-19: progress and lessons learned	245
Function and therapeutic value of astrocytes in neurological diseases	237
Pharmacological targeting of endoplasmic reticulum stress in disease	224
Protein arginine methylation: from enigmatic functions to therapeutic targeting	223
Circadian rhythm as a therapeutic target	210
Advances in targeting ‘undruggable’ transcription factors with small molecules	204
Therapeutic strategies targeting FOXO transcription factors	193
Antibody–drug conjugates come of age in oncology	181
Engineering living therapeutics with synthetic biology	176
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities	173
The emerging role of mass spectrometry-based proteomics in drug discovery	169
Lipogenesis inhibitors: therapeutic opportunities and challenges	168
Targeting Notch in oncology: the path forward	166
Engineering the next generation of cell-based therapeutics	161
Drugging the efferocytosis process: concepts and opportunities	148
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies	148
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation	146
2020 FDA drug approvals	145
Immune targets for therapeutic development in depression: towards precision medicine	142
Modulating biomolecular condensates: a novel approach to drug discovery	142
The PROTACtable genome	141
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease	140
Deuterium in drug discovery: progress, opportunities and challenges	137
Rational combinations of targeted cancer therapies: background, advances and challenges	134
Targeting replication stress in cancer therapy	131
Exosome-based candidates move into the clinic	121
Phenotypic drug discovery: recent successes, lessons learned and new directions	118
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	115
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	114
The glomerular filtration barrier: a structural target for novel kidney therapies	112
The promises and perils of psychedelic pharmacology for psychiatry	105
Improving target assessment in biomedical research: the GOT-IT recommendations	104
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials	104
The therapeutic potential of targeting regulated non-apoptotic cell death	104
Antibodies to combat viral infections: development strategies and progress	100
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders	99
Avidity in antibody effector functions and biotherapeutic drug design	99

Applications of single-cell RNA sequencing in drug discovery and development	94
A tale of two antiviral targets — and the COVID-19 drugs that bind them	92
Trends in COVID-19 therapeutic clinical trials	87
Targeting galectin-driven regulatory circuits in cancer and fibrosis	87
2021 FDA approvals	85
Targeting angiogenesis in oncology, ophthalmology and beyond	84
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems	81